Washington, DC – The Food and Drug Administration did the right thing by approving the first-ever medical treatment for women’s most common sexual complaint and we hope that other safe and effective treatments will be approved. Hypoactive Sexual Desire Disorder (HSDD) is a serious condition experienced by about ten percent of pre-menopausal women, yet it has taken seven years for this drug, Flibanserin (Addyi), to get the green-light.
The National Organization for Women insists on the right of women with HSDD to be taken seriously and to have treatment options that improve their health and quality of life.
Women – no less than men – deserve to have satisfactory sexual experiences and fulfilling intimate relationships.
Elise Coletta , email@example.com
, (951) 547-1241